VTP in the focal therapy of low-risk, localized prostate cancer

We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …

MRI-guided biopsy in the diagnosis of prostate cancer (again)

The results of the so-called PRECISION trial were just published in the New England Journal of Medicine this morning. … READ MORE …

First randomized clinical trial of SBRT reports primary outcome

In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …

Long-term data on active surveillance from MSKCC

A presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data on outcomes of men initially managed on active surveillance at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York over the past 17 years. … READ MORE…

The MEAL study — another update: data coming soon

In October last year we had expressed the hope that data from the Men’s Eating and Living (MEAL) study would be presented at a major medical meeting this year. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

Upcoming clinical trial of PSMA-linked lutetium-177 in recurrent mCRPC

According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …